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ABSTRACT  
Objective: Synthesis and antimicrobial evaluation of some new amides of Thiomorpholine caboxylate. 
Methods: A series of new amides of Thiomorpholine caboxylate were synthesized by reacting 4-tert-butyl 2-methyl thiomorpholine-2,4-
dicarboxylate 1,1-dioxide with primary amines in presence of Trimethyl aluminum in toluene at ambient temperature in good yields. 4-tert-butyl 2-
methyl thiomorpholine-2,4-dicarboxylate 1,1-dioxide was synthesized by reacting tert-butyl thiomorpholine-4-carboxylate 1,1-dioxide with methyl 
chloroformate in presence of LiHMDS (1M in THF) at -78oC for the first time. The newly synthesized compounds were characterized by IR, 1HNMR, 
13C NMR, Mass spectral studies and elemental analysis. 
Results: A series of new amides of Thiomorpholine carboxylate were synthesized in good yields and all the compounds were screened for their In-
vitro antimicrobial activities.  
Conclusion: Preliminary results revealed that the synthesized compounds were showed moderate to good antibacterial and antifungal activity. 
Keywords: Antimicrobial activity, Thiomorpholine, Trimethylaluminum, LiHMDS. 
 
INTRODUCTION 
Thiomorpholine units and amides of various heterocyclic 
compounds have attracted much attention for their remarkable 
pharmacological activities and have been explored as one of the best 
pharmacophores. Thiomorpholine derivaties have diverse biological 
activities that include DPP-IV inhibitors [1], anti-inflammatory [2], 
antioxidant [3-4], anti-microbial[5], hypertensive [6], anaesthatic [7], 
antiplatelet[8], antibacterial & Cytotaxin [9], anti-cancer [10], 
analgesic & hypothertic [11], antimycobacterial [12] and hypnotonic 
[13]. Considering the above facts and our search on Thiomorpholine 
linked biologically potent molecules, we herein report the synthesis 
of some new amides of Thiomorpholine Carboxylate and their 
microbial activity. 
MATERIALS AND METHODS 
All reagents and solvents were purchased from commercial 
suppliers and were purified and dried when necessary by standard 
techniques. The structures of newly synthesized compounds were 
established on the basis of, 1H NMR, FTIR, 13C NMR, mass spectral 
data and elemental analysis. The 1HNMR spectra were recorded on 
Brucker 300 and 400MHz spectrometer using TMS as internal 
standard. The Chemical shifts values are given in δ ppm. The FTIR 
spectra were recorded by using Perkin Elmer FTIR spectrometer 
using a thin film on KBr pellets and frequencies were expressed in 
cm-1. The Mass spectra were recorded by the EI process. The 
elemental analyses were performed on Perkin Elmer CHNS/O 
analyzer 2400. Melting points were determined on open capillaries 
using a cintex melting point apparatus and are uncorrected. Follow 
up of the reactions and checking the purity of the compounds was 
made by thin layer chromatography (TLC) on silica gel precoated 
aluminum sheets (Type 60 GF254; Merck; Germany) and the spots 
were detected by exposure to UV lamp at λ 254 nm for few seconds.  
The synthesis of thiomorpholine moiety was reported by several 
groups and N-substituted thiomorpholines were reported [14]. The 
reactions on C’s of thiomorpholines are very few. In this work, we 
are reporting the synthesis of thiomorpholine carboxylate amides 
for the first time. The synthetic route for thiomorpholine 
carboxylate and amides is represented in scheme 1. The reaction of 
Compound-2 with methylchloroformate in presence of LiHMDS (1M 
in THF) resulted thiomorpholine carboxylate in excellent yield 
(98%). Compound-3 was treated with different amines in presence 
of Trimethyl aluminum (2M in Toluene) to afford new amide 
derivatives of thiomorpholine carboxylate (4a-j) in good yields.  
 




Synthesis of N-tert-butyloxycarbonyl thiomorpholine, 1 
A solution of BOC2O (21.16g, 97 mmol) in dichloromethane (100 
mL) was added to a solution thiomorpholine (10 g, 97 mmol) and 
triethylamine (16.23 mL, 116 mmol) in dichloromethane (500 mL). 
The mixture was stirred for 1 hour at room temperature and 
monitored by TLC. Ethyl acetate (400 mL) was added and the 
organic solution was washed with citric acid (3X250 mL, 1M), water 
(3X250 ml), brine (250 ml), dried over anhydrous sodium sulphate 
and evaporated in vacuo to afford N-tert-butyloxycarbonyl 
thiomorpholine, 1 as a colourless solid (19.5g, 99%).  
Synthesis of tert-butyl thiomorpholine-4-carboxylate 1,1-
dioxide, 2 
N-tert-butyloxycarbonyl thiomorpholine (15 g, 73.89 mmol) was 
dissolved in dichloromethane (500 ml), m-chloroperbenzoic acid 
(25.49 g, 147.78 mmol) was gradually added while cooled with ice 
bath. The reaction mixture was stirred at room temperature for 12h. 
After completion of reaction, was added a saturated aqueous 
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solution of sodium thiosulfate, extracted with ethyl acetate, washed 
with brine, dried over anhydrous sodium sulfate and concentrated 
under reduced pressure to afford crude. The crude was purified by 
column chromatography using 30-35% ethyl acetate in hexane as 
eluent to afford tert-butyl thiomorpholine-4-carboxylate 1,1-dioxide, 
2 as off white solid. 
Synthesis of 4-tert-butyl 2-methyl thiomorpholine-2,4-
dicarboxylate 1,1-dioxide, 3  
To a stirred solution of tert-butyl thiomorpholine-4-carboxylate 1,1-
dioxide (42.55 mmol) in THF (300 mL) was added dropwise 1M 
solution of LiHMDS (42.55 mmol) at -78oC and the resulting reaction 
mixture was stirred under the nitrogen atmosphere for 1h. 
Methylchloroformate (42.55 mmol) was added drop wise to the 
above reaction mixture and stirred for 2h at -780C. The reaction 
mixture was added to NH4Cl solution (200 mL) and the product was 
extracted with EtOAc (3 x 150 mL) to obtain crude compound. The 
crude was recrystalized from diethylether, filtered and dried under 
vacuum to afford 4-tert-butyl 2-methyl thiomorpholine-2,4-
dicarboxylate 1,1-dioxide, 3 as off white solid. 
General Method for synthesis of 4a-j [15] 
To a stirred solution of alkylamine (0.34 mmol) in Toluene was 
added Trimethylaluminum (2M in Toluene, 1.02 mmol) at 00C and 
allowed to stir for 15 min. A solution of 4-tert-butyl 2-methyl 
thiomorpholine-2,4-dicarboxylate 1,1-dioxide (0.34 mmol) in 
toluene was added drop wise to the reaction mixture under N2 and 
stirred for overnight at room temperature. The reaction mixture was 
poured into crushed ice, added 2N HCl, basified to pH 9- 10 with 
NH4OH and organic phase was separated.  
The aqueous phase was washed with more CH2Cl2 the combined 
organic phases were washed with brine, dried over Na2SO4 and 
concentrated. The crude was chromatographed on silica gel (100-
200 mesh), eluting with a gradient mixture of (30-35%) ethylacetate 
in hexane as eluent, giving (4a-f) as pure compounds (Table 1). 
 
Table 1: It represents molecular formulas and yields of final compounds (4a-j) 
S. No. Compound R Molecular Formula (4a-j) Molecular Weight Yield (%) 
1 4a 
 
C18H26N2O5S 382.474 85 
2 4b 
 
C17H22N4O6S 410.445 82 
3 4c 
 

































Spectral data  
N-tert-butyloxycarbonyl thiomorpholine, 1: Yield (99%); 
Offwhite solid: 1HNMR (CDCl3, 300 MHz): 3.71-3.64 (m, 4H), 2.60-
2.52 (m, 4H), 1.45 (s, 9H); ESI-MS 148 (M+- t-Butyl) 
tert-butyl thiomorpholine-4-carboxylate 1,1-dioxide, 2:Yield 
(89%); Off white solid; M. P: 157 - 159 oC: 1H NMR (CDCl3, 300Mz): δ 
4.0 - 3.9 (m, 4H), 3.10 - 2.90 (m, 4H), 1.44 (s, 9H): ESI-MS: 180 (M+- t-
Butyl) 
4-tert-butyl 2-methyl thiomorpholine-2,4-dicarboxylate 1,1-
dioxide,3:Yield (98%); Off white Solid; M. P: 110-113oC; 1H NMR 
(DMSO-d6, 400MHz): δ 4.37 (br, 1H), 4.11-3.86 (m, 3H), 3.72-3.47 
(br, 4H), 3.41- 3.36 (br, 1H), 3.26-3.25(m, 1H), δ 1.41 (s, 9H); ESI-
MS: 180 (M+- t-Butyl) 
tert-butyl 2-(phenethylcarbamoyl) thiomorpholine-4-
carboxylate 1,1-dioxide, 4a: Offwhite solid; M. P: 95-98oC; FTIR 
(KBr, cm-1);3385, 3072, 1685, 1585, 1273, 1106, 757; 1H NMR 
(DMSO-d6, 400MHz): δ 8.40-8.20 (br, 1H), 7.40- 7.10 (m, 5H), 4.18 - 
3.90 (m, 2H), 3.80 - 3.50 (m, 5H), 3.20 - 3.10 (m, 2H), 2.80 - 2.60 (m, 
2H), 1.41 (s, 9H). 13C–NMR (DMSO, 125Mz):δ 163.42 (CONH), 
153.18 (COBoc), 139.02 (Ar-CH),128.63(2,Ar-CH),128.36(2,Ar-CH), 
126.18 (CH), 80.00 (-(CH3)3CO-), 63.01(CH), 50.81(CH2), 49.25(CH2), 
45.66 (CH2), 40.58 (NHCH2), 34.85 (Ar-CH2), 27.79 (CH3):EI-MS 
(m/z): 327(M+- t-Butyl); Anal. Cald. for C18H26N2O5S; C, 56.52; H, 
6.85; N, 7.32; O, 20.92; S, 8.38; Found: C, 56.48; H, 6.81; N, 7.36; O, 
20.88; S, 8.34 
tert-butyl 2-((2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl) 
carbamoyl) thiomorpholine -4-carboxylate 1,1-dioxide, 4b; 
Offwhite solid. M. P: 258- 260oC; FTIR (KBr, cm-1): 3388, 2978, 
1693,1566, 1295, 868, 710; 1H NMR (DMSO-D6, 400MHz): δ 10.62 
(s, 1H), 10.55 (s, 1H), 10.22-10.18(br, 1H), 7.46 (s, 1H), 7.02-6.85 
(br, 1H), 6.87-6.85 (d, j= 8.0Hz, 1H), 4.40-4.20 (br, 2H), 4.02 -3.90(m, 
1H), 3.80-3.70 (m, 1H), 3.70-3.55 (m, 1H), 3.42.-3.30 (m, 1H), 3.22-
3.16 (m, 1H), 1.41 (s, 9H). EI-MS (m/z): 355(M+- t-Butyl); Anal. Cald. 
for C17H22N4O6S: C, 49.75; H, 5.40; N, 13.65; O, 23.39; S, 7.81;Found; 
C, 49.68; H, 5.46; N, 13.60; O, 23.32; S, 7.78 
tert-butyl 2-(benzylcarbamoyl)thiomorpholine-4-carboxylate 
1,1-dioxide, 4c: Offwhite solid; M. P: 85-90oC; FTIR (KBr, cm-1): 
3345, 3088, 1687,1609,1267,1100, 833, 751: 1H NMR (DMSO-D6, 
400MHz): δ 8.80-8.65 (br, 1H), 7.4-7.2(m, 5H), 4.5-4.1 (br, 4H), 
3.95-3.85 (m, 1H), 3.80-3.50 (m, 3H), 3.20-3.10 (m, 1H), 1.35(s, 9H). 
EI-MS (m/z): 313 (M+- t-Butyl); Anal. Cald. for C17H24N2O5S; C, 55.42; 
H, 6.57; N, 7.60; O, 21.71; S, 8.70; Found; C, 55.39; H, 6.50; N, 7.58; O, 
21.61; S, 8.65. 
tert-butyl 2-[(2-hydroxy-6-methylphenyl) carbamoyl] thio 
morpholine-4-carboxylate 1,1-dioxide, 4d; Light yellow solid; M. 
P; 90- 92; FTIR (KBr, cm-1): 3601, 3341,3064, 
1693,1601,1521,1203, 850, 711 1H NMR (DMSO-d6, 400MHz): δ 
9.44(s, 1H), 9.35-9.18(b, 1H), 6.98 (t, j= 7.6Hz, j= 8Hz,1H), 6.71-6.64 
(dd, j= 7.6Hz, j= 8.0Hz, 2H), 4.40-4.30(m, 1H), 4.25-4.15 (m, 2H), 
4.00-3.70 (m, 2H), 3.55-3.40 (m, 2H), 3.20-3.10 (m, 1H) 2.08 (s, 
3H),1.5-1.25 (br, 9H); EI-MS (m/z):329(M+- t-Butyl); Anal. Cald. for 
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C17H24N2O6S; C, 53.11; H, 6.29; N, 7.29; O, 24.97; S, 8.34;Found; C, 
53.08; H, 6.26; N, 7.27; O, 24.94; S, 8.30 
tert-butyl 2-(m-tolylcarbamoyl)thiomorpholine-4-carboxylate 
1,1-dioxide, 4e: Brownsolid: M. P; 82- 84oC; FTIR (KBr, cm-1): 
3376, 3068, 1696,1606,1270,1099, 847, 751: 1H NMR (DMSO-d6, 400 
MHz): δ 8.80-8.60 (br, 1H), 7.25 (s, 1H), 7.20-7.00 (m, 3H), 4.50-4.11 
(m, 3H), 4.10-3.80 (m, 2H), 3.80-3.50 (m, 1H), 3.20-3.10 (m, 2H), 
2.25 (s, 3H), 1.40 (s, 9H); EI-MS (m/z):327(M+- t-Butyl); Anal. Cald. 
for C18H26N2O5S; C, 56.52; H, 6.85; N, 7.32; O, 20.92; S, 8.38; Found: 
C, 56.48; H, 6.80; N, 7.28; O, 20.94; S, 8.34.  
tert-butyl 2-([1,1'-biphenyl]-2-ylcarbamoyl)thiomorpholine-4-
carboxylate 1,1-dioxide, 4f: Offwhite solid; M. P: 148-150; FTIR 
(KBr, cm-1): 3359, 3072, 1695,1588,1269,1098,1008, 759: 1H NMR 
(DMSO-d6, 300MHz): δ 9.65-9.58 (br, 1H), 7.7-7.50(br, 1H), 7.50-
7.30 (m, 8H), 4.4-4.0 (br, 3H), 3.80-3.40 (br, 3H), 3.29-3.10 (m, 1H), 
1.4 (s, 9H); EI-MS (m/z):375 (M+- t-Butyl); Anal. Cald. for 
C22H26N2O5S; C, 61.38; H, 6.09; N, 6.51; O, 18.58; S, 7.45; Found; C, 
61.30; H, 6.15; N, 6.50; O, 18.52: S, 7.42. 
tert-butyl 2-(hydrazinecarbonyl)thiomorpholine-4-carboxylate 
1,1-dioxide, 4g: Offwhite solid; M. P; 120- 125; FTIR (KBr, cm-1): 
3348, 2933, 1689, 1590, 1426, 1298, 875, 611: 1H NMR (DMSO-d6, 
400MHz): δ 9.50- 9.30 (b, 1H), 4.50-4.30 (m, 2H), 4.20-4.00 (b, 1H), 
4.00-3.90 (b, 1H), 3.80-3.60 (m, 2H), 3.60-3.40 (m, 2H), 3.15-3.10 (m, 
1H), 1.40 (s, 9H), EI-MS (m/z): 238 (M+- t-Butyl); Anal. Cald. for 
C17H24N2O6S; C, 53.11; H, 6.29; N, 7.29; O, 24.97; S, 8.34;Found; C, 
53.08; H, 6.26; N, 7.27; O, 24.94; S, 8.30 
tert-butyl 2-((4-methylbenzyl)carbamoyl)thiomorpholine-4-
carboxylate 1,1-dioxide, 4h: Offwhite solid; M. P; 98- 100; FTIR 
(KBr, cm-1): 3333, 3068, 1696,1511, 1456, 1256, 847, 769: 1H NMR 
(DMSO-d6, 400MHz): δ 8.60-8.80 (b, 1H), 7.35 (d, J=8.2 Hz, 2H), 7.05 
(d, J=8.2 Hz, 2H), 4.40-4.11 (m, 3H), 4.10-3.80 (m, 2H), 3.80-3.50 (m, 
2H), 3.20-3.10 (m, 2H), 2.25 (s, 3H), 1.40 (s, 9H): EI-MS (m/z): 
327(M+- t-Butyl); Anal. Cald. for C17H24N2O6S; C, 53.11; H, 6.29; N, 
7.29; O, 24.97; S, 8.34;Found; C, 53.08; H, 6.26; N, 7.27; O, 24.94; S, 
8.30 
tert-butyl 2-((3,5-dimethylphenyl)carbamoyl)thiomorpholine-
4-carboxylate 1,1-dioxide, 4i: Offwhite solid; M. P; 105-108; FTIR 
(KBr, cm-1):3364, 3092, 1696,1608,1455,1211, 867, 697: 1H NMR 
(DMSO-d6, 400MHz): δ 9.00 (s, 1H), 7.30 (s, 2H), 6.70(s, 1H), 4.40-
4.30(m, 1H), 4.25-4.15 (m, 2H), 4.00-3.70 (m, 2H), 3.55-3.40 (m, 1H), 
3.20-3.10 (m, 1H) 2.25 (s, 6H),1.41 (s, 9H); EI-MS (m/z): 327(M+- t-
Butyl); Anal. Cald. for C17H24N2O6S; C, 53.11; H, 6.29; N, 7.29; O, 
24.97; S, 8.34;Found; C, 53.08; H, 6.26; N, 7.27; O, 24.94; S, 8.30 
tert-butyl 2-((4-hydroxyphenyl)carbamoyl)thiomorpholine-4-
carboxylate 1,1-dioxide, 4j: Offwhite solid; M. P; 95-98; FTIR 
(KBr, cm-1): 3625, 3385, 3084,1674,1482, 1451, 981, 741: 1H NMR 
(DMSO-d6, 400MHz): δ 9.50(s, 1H), 9.40-9.20(b, 1H), 7.33 (d, J=6.8 
Hz, 2H), 6.67 (d, J=6.9 Hz, 2H), 4.40-4.00 (m, 3H), 4.00-3.60 (m, 2H), 
3.55-3.40 (m, 1H), 3.20-3.10 (m, 1H), 1.42(s, 9H); EI-MS (m/z): 
315(M+- t-Butyl); Anal. Cald. for C17H24N2O6S; C, 53.11; H, 6.29; N, 
7.29; O, 24.97; S, 8.34;Found; C, 53.08; H, 6.26; N, 7.27; O, 24.94; S, 
8.30.
 
Table 2: Zone of inhibition (mm) data of synthesized compounds (4a-j) 
S. No. Compound B. subtilis  S. aureus  E. coli  S. typhi  A. niger  C. albicans 
1 4a 8  7 7 6 10 8 
2 4b 11 10 12 11 13 11 
3 4c 9 6 8 4 9 6 
4 4d 7 5 9 6 11 9 
5 4e 9 4 8 6 10 8 
6 4f 7 5 6 4 12 8 
7 4g 9 7 10 7 8 6 
8 4h 7 6 9 8 10 8 
9 4i 8 7 9 6 11 8 
10 4j 8 6 8 4 12 7 
11 Control - - - - - - 
12 A 16 15 19 16 - - 
13 B - - - - 19 17 
Control=DMSO, A=Ciprofloxacin and B=Ketoconazole 
 
RESULTS AND DISCUSSION 
Antibacterial activity 
The antibacterial activity of all the synthesized compounds (4a-j) 
was examined against different Gram-positive (Bacillus subtilise and 
Staphylococcus aureus) and Gram-negative (Escherichia coli and 
Salmonella typhii) organisms by measuring zone of inhibition. The 
antibacterial activity was performed by Agar diffusion method at the 
concentration level of 250μg/ml. Ciprofloxacin was used as the 
standard drug at a concentration of 250μg/ml. Nutrient agar was 
used as culture media and DMSO was used as the solvent control. 
The results of the antibacterial activity are shown in Table 2. 
Antifungal activity 
The antifungal activity of all the synthesized compounds (4a-j) was 
examined against Aspergillus niger and Candida albicans by measuring 
zone of inhibition. The antifungal activity was performed by Agar 
diffusion method at the concentration level of 250μg/ml. Ketoconazole 
was used as a standard drug at a concentration of 250μg/ml. Sabouraud 
dextrose agar was used as culture media and DMSO was used as solvent 
control. The results of the antifungal activity are shown in Table 2. 
CONCLUSION 
In accordance with the data obtained from antimicrobial activity, 4b 
showed good antimicrobial activity against the tested microbes 
among all the synthesized amides and rest of the compounds 
showed moderate antimicrobial activity against tested microbes. 
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